Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Nov 21;208(12):2357–2366. doi: 10.1084/jem.20111171

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 Caskey et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — Validation of the transcriptional profiling on PBMCs. (a) Poly ICLC induced systemic secretion of IFNs. Plasma concentrations of IFN-γ, IFN-α, and CXCL10 at time points after poly ICLC (blue, n = 8) or placebo (red, n = 4) were analyzed by two-way ANOVA. Error bars represent the standard error of the mean concentrations. Poly ICLC effects were significant at days 1–3 (*, P < 0.001). (b and c) PBMCs from four donors were stimulated with 50 µg/ml poly IC for 13 h plus 10 µg/ml IFNAR antibody or isotype control antibody. RNA was extracted for transcriptional analysis. (b) Differential gene expression in blood 1 d after in vivo poly ICLC (x axis, n = 8) was compared with differential gene expression in PBMCs after 13 h of poly IC stimulation in vitro (y axis, n = 4). Genes falling on the identity line (dark gray) are equally regulated in both systems. A loss curve (dashed blue) is used to infer the local trend between the two systems. IRGs are in red. Text labels are added to points for genes with FC > 2 at 5% FDR in at least one comparison. (c) Log₂(FC) of IRGs after in vitro poly IC with blocking anti-IFNAR mAb (y axis) and after in vitro poly IC with control antibody (x axis).